Phase 1
Completed N=16
Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management
Source: ClinicalTrials.gov NCT04343092 ↗Enrolled (actual)
16
Serious AEs
0.0%
Results posted
Nov 2020
Primary outcomePrimary: Number of Cured Patients — 16 Participants
Summary
Comparing the effectiveness of Ivermectin( IVM) +Hydroxychloroquin + azithromycin (AZT) group to Hydroxychloroquin (HCQ) + azithromycin (AZT)
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Cured Patients |
16 | — |
| SECONDARY Time to Cure of COVID-19 Patients in the IVM +HCQ+AZT Group |
7.62 | 0.05 |
Eligibility Criteria
Inclusion Criteria
-1. Patients with age above 18 years and any gender with definite Dx of covid19 and pneumonia in the ward according to the clinical, laboratory, and imaging criteria.
- Understands and agrees to comply with planned study procedures.
Exclusion Criteria
- Patients with hypersensitivity or severe adverse effects to Ivermectin
- Renal impairment
- Hepatic impairment.
- Pregnancy or a desire to become pregnant (drug considered pregnancy category c)
- Breast feeding.
- Patient with covid 19 positive and mild no pneumonia
- Children under the age of five or those who weigh less than 15 kilograms
Data sourced from ClinicalTrials.gov (NCT04343092). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.